Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 296

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 296
---
ness and all interest accrued at any time prior to the maturity date without the prior written consent of the lender and without payment of any premium or penalty. CONTINGENT PAYMENT OBLIGATIONS As of June 30, 2025, we do not have any non -cancellablepurchase commitments. The Group has contingency payment obligations under each of the license agreements, such as milestone payments, royalties, research and development funding, if certain condition or milestone is met. Milestone payments are to be made upon achievements of certain conditions, such as Investigational New Drugs (“IND”) filing or U.S. Food and Drug Administration (“FDA”) approval, first commercial sale of the licensed products, or other achievements. The aggregate amount of the milestone payments that we are required to pay up to different achievements of conditions and milestones for all the license agreements signed as of June 30, 2025 are as below:

|                                                        |     | Amount |           |
| (unaudited)                                            |     |        |           |
| Drug molecules: up to the conditions and milestones of |     |        |           |
| From entering phase 1 to before first commercial sale  |     |        |   920,000 |
| First commercial sale                                  |     |        |   800,000 |
| Net sales amount more than certain threshold in a year |     |        | 7,000,000 |
| Subtotal                                               |     | $      | 8,720,000 |

For the six months ended June 30, 2025 and 2024, the Group incurred $nil and $60,659 milestone payments respectively. For the six months ended June 30, 2025 and 2024, the Group did not incur any royalties or research and development funding. CONDENSED SUMMARY OF OUR CASH FLOWS

|                                           |     | Six months 
 ended      
 June 30,   
 2025       |           |   |     | Six months 
 ended      
 June 30,   
 2024       |            |   |
|:------------------------------------------|:----|:-----------|----------:|:--|:----|:-----------|-----------:|:--|
|                                           |     | -Unaudited |           |   |     | -Unaudited |            |   |
| Net cash used in operating activities     |     | $          |  (816,544 | ) |     | $          | (1,280,887 | ) |
|